GO:0043484 regulation of RNA splicing: Spliceosome Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043484 regulation of RNA splicing describes any process that modulates the frequency, rate or extent of RNA splicing, the removal of introns and joining of exons in pre-mRNA.
• Splicing is executed by the spliceosome, a dynamic ribonucleoprotein machine whose core components include snRNPs and associated proteins such as SF3B1, U2AF1, RBM39 and PRPF8.
• Regulation occurs at multiple levels: splice site selection, exon definition, RNA-binding protein (RBP) competition, and post-translational modification of splicing factors.
• Dysregulation of RNA splicing is a hallmark of cancer, neurodegeneration and developmental disorders, with recurrent mutations in SF3B1, U2AF1 and SRSF2 in myeloid neoplasms.
• Key regulatory proteins include PTBP1, which controls neuronal alternative splicing, and Brr2, an RNA helicase essential for spliceosome activation.
• CRISPR-based knockout, point mutation, knock-in and overexpression models enable causal interrogation of splicing regulators in disease and development.
Description
Regulation of RNA splicing (GO:0043484) encompasses all processes that modulate the frequency, rate or extent of RNA splicing, the essential post-transcriptional step in which introns are removed and exons are ligated to form mature mRNA. This regulation is critical because alternative splicing allows a single gene to produce multiple protein isoforms, expanding proteome diversity and enabling tissue-specific and developmental-stage-specific gene expression. The spliceosome, a large ribonucleoprotein complex, carries out the catalytic steps, and its activity is controlled by cis-acting elements, trans-acting RNA-binding proteins (RBPs), and signaling pathways that modify splicing factors. For researchers, understanding GO:0043484 is central to dissecting gene expression programs in health and disease. Dysregulated splicing contributes to cancer, neurodegeneration, and genetic disorders, and mutations in core spliceosome genes such as SF3B1 and U2AF1 are recurrent in hematological malignancies. Moreover, splicing regulators like PTBP1 and Brr2 are emerging therapeutic targets. This article provides a research-grade overview of the mechanisms, key genes, disease links, and experimental models used to study regulation of RNA splicing, with a focus on CRISPR-based approaches for functional validation.
regulation of RNA splicing At A Glance
| GO ID | GO:0043484 |
|---|---|
| GO term | regulation of RNA splicing |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Modulates the frequency, rate or extent of RNA splicing, including alternative splice site selection |
| Core machinery | Spliceosome (snRNPs U1, U2, U4/U6, U5), associated proteins (SF3B1, U2AF1, PRPF8, Brr2) |
| Key regulators | RNA-binding proteins (PTBP1, SRSF1, hnRNPs), splicing factors, signaling kinases |
| Disease relevance | Cancer, neurodegeneration, developmental disorders, splicing factor mutations |
| Research methods | RNA-seq, CLIP-seq, CRISPR screens, minigene reporters, proteomics |
What Is GO:0043484?
GO:0043484 regulation of RNA splicing is defined as any process that modulates the frequency, rate or extent of RNA splicing. RNA splicing itself is the process of removing introns from a pre-mRNA transcript and joining exons to generate a mature mRNA molecule. Regulation can occur at the level of splice site recognition, spliceosome assembly and activation, catalytic activity, and the choice between alternative splice sites, thereby influencing which mRNA isoforms are produced.
Why Is regulation of RNA splicing Important in Cell Biology?
Regulation of RNA splicing is fundamental to gene expression because it determines the coding capacity and stability of most human transcripts. Alternative splicing affects nearly all multi-exon genes, and its dysregulation is causally linked to cancer, neurodegeneration, and inherited diseases. Understanding how splicing is regulated provides insights into basic biology and identifies therapeutic vulnerabilities, such as splicing factor mutations in leukemia and splicing modulators in solid tumors.
• Expands proteome diversity by generating multiple mRNA isoforms from a single gene.
• Controls tissue-specific and developmental-stage-specific gene expression programs.
• Mutations in core spliceosome genes (SF3B1, U2AF1, SRSF2) drive myeloid neoplasms and are associated with prognosis.
• Dysregulated splicing contributes to neurodegeneration, including PTBP1-mediated neuronal splicing defects.
• Splicing regulators are emerging drug targets; modulators of SF3B1 and other factors are in clinical trials.
• Viral pathogens hijack splicing regulation to promote their own gene expression.
• Circular RNAs and other noncoding RNAs can regulate splicing in vascular remodeling and other processes.
• CRISPR screens have identified specialized regulatory functions of core spliceosome components.
• RNA-binding proteins (RBPs) are frequently dysregulated in tumors and affect splicing, stability and translation.
• Understanding splicing regulation informs RNA-based therapeutics and biomarker discovery.
What Happens During regulation of RNA splicing?
Splice site recognition and exon definition
In simple terms: The cell marks which parts of the RNA should be kept and which should be removed.
Regulation begins with recognition of the 5' and 3' splice sites and the branch point by U1 snRNP and associated factors. Exon definition, particularly in mammalian genes with large introns, involves interactions across exons that are stabilized by SR proteins and hnRNPs. The strength of these cis-elements and the availability of trans-acting factors determine whether an exon is included or skipped, a key point of regulation.
Spliceosome assembly and activation
In simple terms: A molecular machine called the spliceosome builds up on the RNA and gets switched on.
The spliceosome assembles stepwise: U1 and U2 snRNPs recognize the splice sites, followed by recruitment of the U4/U6.U5 tri-snRNP. Activation requires the RNA helicase Brr2, which unwinds U4/U6, and other ATP-dependent rearrangements. This step is tightly regulated by post-translational modifications and auxiliary proteins, and its disruption alters splicing patterns.
Catalysis and exon ligation
In simple terms: The machine cuts out the intron and stitches the exons together.
After activation, the spliceosome catalyzes two transesterification reactions that remove the intron and join the exons. The catalytic core undergoes dynamic conformational changes, and regulation of this step can influence splicing fidelity and alternative isoform production. Errors in catalysis can lead to intron retention or aberrant exon joining, which are associated with disease.
Alternative splicing decisions
In simple terms: The cell can choose different combinations of exons to make different versions of a protein.
Alternative splicing is regulated by the combinatorial action of RNA-binding proteins that enhance or silence splice site usage. For example, PTBP1 represses neuronal-specific exons, while SR proteins promote inclusion. Signaling pathways can modify these regulators, allowing extracellular cues to alter splicing programs.
Quality control and coupling to transcription
In simple terms: Splicing is checked for mistakes and is coordinated with the process of copying DNA into RNA.
Splicing is coupled to transcription, and the C-terminal domain of RNA polymerase II recruits splicing factors. Surveillance mechanisms, including nonsense-mediated decay, degrade aberrant transcripts. Regulation of these quality-control steps ensures that only correctly spliced mRNAs are exported and translated.
Key Genes Involved in GO:0043484 regulation of RNA splicing
The following genes encode core spliceosome components, auxiliary splicing factors, and RNA-binding proteins that regulate RNA splicing (GO:0043484).
| Gene | Major Role | Research Relevance |
|---|---|---|
| SF3B1 | Core spliceosome component; recognizes branch point | Recurrently mutated in myelodysplastic syndromes and other cancers |
| U2AF1 | Auxiliary factor for 3' splice site recognition | Mutations in myeloid neoplasms alter splicing |
| SRSF2 | SR protein; promotes exon inclusion | Mutations in leukemia and myelodysplasia |
| PTBP1 | RNA-binding protein; represses neuronal exons | Key regulator of neuronal development and reprogramming |
| RBM39 | Splicing factor; interacts with SF3B1 | Target of anticancer sulfonamides; splicing regulation |
| PRPF8 | Core component of U5 snRNP | Mutations cause retinitis pigmentosa; spliceosome function |
| BRR2 (SNRNP200) | RNA helicase; activates spliceosome | Essential for splicing; mutations in retinitis pigmentosa |
| SRSF1 | SR protein; promotes exon inclusion | Oncogenic splicing factor; overexpressed in tumors |
| HNRNPA1 | hnRNP; modulates splice site selection | Implicated in cancer and neurodegeneration |
| U1 snRNP (RNU1) | Recognizes 5' splice site | Core splicing machinery; target of regulation |
| U2 snRNP (RNU2) | Recognizes branch point | Core splicing machinery; regulated by SF3B1 |
| U4/U6.U5 tri-snRNP | Pre-assembled tri-snRNP | Requires Brr2 for activation |
| SRSF2 | SR protein; modulates exon inclusion | Mutations in myeloid neoplasms |
| HNRNPH | hnRNP; regulates alternative splicing | Implicated in cancer and neuronal splicing |
| CIRC (circEsyt2) | Circular RNA; regulates splicing in VSMC | Vascular remodeling; splicing regulation |
| SF1 | Splicing factor 1; branch point recognition | Core splicing factor; regulated during assembly |
| U2AF2 | Auxiliary factor for 3' splice site | Regulated in splicing and cancer |
How Is regulation of RNA splicing Regulated?
Regulation of RNA splicing is itself controlled by multiple layers. Transcription elongation rates influence splice site choice, and signaling pathways such as those involving SR protein kinases (e.g., CLK, SRPK) modify splicing factors to alter their activity. RNA-binding proteins can compete or cooperate with core spliceosome components, and their expression levels are often dysregulated in cancer. Additionally, circular RNAs and other noncoding RNAs can sequester splicing factors, as shown for circEsyt2 in vascular smooth muscle cells. Post-translational modifications of spliceosome components, including phosphorylation and ubiquitination, modulate assembly and catalytic activity.
regulation of RNA splicing and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SF3B1 | Myelodysplastic syndromes, leukemia | Knock-in of hotspot mutations in hematopoietic cells |
| PTBP1 | Neurodegeneration, neuronal development | Knockout and overexpression in neuronal differentiation models |
| PRPF8 | Retinitis pigmentosa | Knock-in of patient mutations in retinal organoids |
| U2AF1 | Myeloid neoplasms | Point mutation knock-in in cell lines |
| SRSF2 | Leukemia, myelodysplasia | Knockout and mutant overexpression in hematopoietic cells |
Cancer
Dysregulation of RNA splicing is a hallmark of cancer. Recurrent mutations in SF3B1, U2AF1, and SRSF2 are found in myelodysplastic syndromes, acute myeloid leukemia, and other malignancies, leading to altered splicing of genes involved in proliferation and differentiation. Overexpression of splicing factors such as SRSF1 promotes oncogenic isoforms, and splicing modulators are being tested in clinical trials.
Neurodegeneration and neurological disorders
Neurons are particularly sensitive to splicing defects. PTBP1 regulates neuronal alternative splicing, and its downregulation is required for neuronal differentiation; misregulation is implicated in neurodegeneration. Mutations in spliceosome components like PRPF8 and Brr2 cause retinitis pigmentosa, a retinal degeneration. Global splicing dysregulation is observed in Alzheimer's disease and amyotrophic lateral sclerosis.
Vascular remodeling
Circular RNA circEsyt2 regulates vascular smooth muscle cell remodeling via splicing regulation, highlighting the role of noncoding RNAs in splicing control in cardiovascular disease.
From regulation of RNA splicing-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a splicing factor affect cell viability? | CRISPR knockout in cancer cell lines |
| Does a specific mutation alter splice site selection? | Point mutation knock-in via CRISPR |
| Does a splicing regulator control neuronal differentiation? | Knockout/overexpression in iPSC-derived neurons |
| Can a splicing factor be tagged for localization studies? | Tagged knock-in (e.g., GFP) at endogenous locus |
| Does overexpression of an oncogenic splicing factor transform cells? | CRISPR-mediated overexpression in primary cells |
| Which splicing regulators are essential in a disease context? | Genome-wide CRISPR library screening |
How to Study the regulation of RNA splicing Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptome-wide splicing patterns | Differential exon usage after knockout/knockdown |
| CLIP-seq | RNA binding sites of proteins | Mapping PTBP1 or SR protein targets |
| CRISPR screen | Gene essentiality and splicing regulation | Identifying novel splicing regulators |
| Minigene assay | Splice site usage in reporter | Testing cis-element mutations |
| RT-PCR | Specific isoform ratios | Validation of splicing changes |
| Proteomics | Protein interactions and modifications | Spliceosome composition and dynamics |
| Ribo-seq | Translation efficiency of spliced mRNAs | Linking splicing to protein output |
RNA sequencing and splice variant analysis
RNA-seq is the primary method to profile splicing changes transcriptome-wide. Computational tools quantify exon inclusion levels (PSI) and identify differential splicing events upon perturbation of candidate regulators.
CLIP-seq and RNA-binding protein mapping
Crosslinking and immunoprecipitation followed by sequencing (CLIP-seq) maps the binding sites of splicing regulators on RNA, revealing direct targets and regulatory mechanisms.
CRISPR screens for splicing regulators
Genome-wide CRISPR knockout or interference screens can identify genes that regulate specific splicing events or cell fitness, as demonstrated for core spliceosome components.
Minigene reporters and splicing assays
Minigene constructs containing specific exons and introns are used to test the effect of cis-elements and trans-factors on splice site selection in a controlled system.
How CRISPR Can Be Used to Study GO:0043484 regulation of RNA splicing
Knockout
CRISPR knockout of splicing regulators (e.g., PTBP1, SF3B1) enables loss-of-function studies to determine their role in splicing and cell phenotypes. Knockout cell models are essential for dissecting essential versus redundant factors.
Point Mutation
Point mutation knock-in models, such as SF3B1 K700E or U2AF1 S34F, recapitulate disease-associated mutations and allow study of altered splicing patterns and drug responses.
Knock-in
Tagged knock-in (e.g., GFP or HA) at endogenous loci facilitates localization and interaction studies of splicing factors without overexpression artifacts.
Overexpression
CRISPR-mediated overexpression of splicing factors (e.g., SRSF1) can model oncogenic transformation and identify downstream splicing events.
How EDITGENE Supports regulation of RNA splicing Research
Researchers studying regulation of RNA splicing-related genes often need to determine whether a candidate gene is causally involved in splicing regulation, disease progression, or therapeutic response. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for regulation of RNA splicing research.
Frequently Asked Questions About regulation of RNA splicing
What is GO:0043484 regulation of RNA splicing?
GO:0043484 is a Gene Ontology biological process term defined as any process that modulates the frequency, rate or extent of RNA splicing, the removal of introns and joining of exons in pre-mRNA.
What genes are involved in regulation of RNA splicing?
Key genes include core spliceosome components such as SF3B1, U2AF1, PRPF8, and BRR2, as well as regulatory RNA-binding proteins like PTBP1, SRSF1, and hnRNPs.
How is RNA splicing regulated?
RNA splicing is regulated by cis-acting elements, trans-acting RNA-binding proteins, spliceosome assembly and activation, post-translational modifications, and coupling to transcription.
Why is regulation of RNA splicing important in cancer?
Mutations in splicing factors like SF3B1 and U2AF1 are common in myeloid neoplasms and alter splicing of genes controlling proliferation and differentiation, making splicing a therapeutic target.
What diseases are linked to splicing dysregulation?
Diseases include myelodysplastic syndromes, leukemia, retinitis pigmentosa, neurodegeneration, and cardiovascular remodeling.
What is the role of PTBP1 in RNA splicing?
PTBP1 is an RNA-binding protein that represses neuronal-specific exons and is essential for neuronal development and reprogramming.
How can CRISPR be used to study RNA splicing regulation?
CRISPR knockout, point mutation knock-in, tagged knock-in, and overexpression models allow causal interrogation of splicing regulators in disease and development.
What methods are used to study regulation of RNA splicing?
Common methods include RNA-seq, CLIP-seq, minigene reporters, CRISPR screens, and proteomics.
What is the spliceosome and how does it relate to GO:0043484?
The spliceosome is the ribonucleoprotein machine that catalyzes splicing; its assembly and activity are major points of regulation under GO:0043484.
Can splicing regulation be targeted therapeutically?
Yes, splicing modulators and antisense oligonucleotides are being developed, especially for cancers with splicing factor mutations and genetic splicing disorders.
Conclusion
Regulation of RNA splicing (GO:0043484) is a central node in post-transcriptional gene control, integrating signals from transcription, RNA-binding proteins, and the spliceosome to shape the transcriptome. Its dysregulation underlies a broad spectrum of human diseases, from leukemia to neurodegeneration. CRISPR-based models are indispensable for dissecting the causal roles of splicing regulators and for validating therapeutic targets. EDITGENE offers end-to-end services to generate such models and accelerate discoveries in splicing biology.
References
- 1. Choquet K et al.. 2025. The regulation and function of post-transcriptional RNA splicing.. Nat Rev Genet 26(6):378-394 PMID: 40217094
- 2. Rogalska ME et al.. 2024. Transcriptome-wide splicing network reveals specialized regulatory functions of the core spliceosome.. Science 386(6721):551-560 PMID: 39480945
- 3. Bonnal SC et al.. 2020. Roles and mechanisms of alternative splicing in cancer - implications for care.. Nat Rev Clin Oncol 17(8):457-474 PMID: 32303702
- 4. Absmeier E et al.. 2016. Functions and regulation of the Brr2 RNA helicase during splicing.. Cell Cycle 15(24):3362-3377 PMID: 27792457
- 5. Qin H et al.. 2020. RNA-binding proteins in tumor progression.. J Hematol Oncol 13(1):90 PMID: 32653017
- 6. Zheng ZM. 2004. Regulation of alternative RNA splicing by exon definition and exon sequences in viral and mammalian gene expression.. J Biomed Sci 11(3):278-94 PMID: 15067211
- 7. Gong X et al.. 2021. Circular RNA circEsyt2 regulates vascular smooth muscle cell remodeling via splicing regulation.. J Clin Invest 131(24) PMID: 34907911
- 8. Liu HL et al.. 2023. The role of RNA splicing factor PTBP1 in neuronal development.. Biochim Biophys Acta Mol Cell Res 1870(7):119506 PMID: 37263298
